Medical Journals

Anti-inflammatory Mechanisms of Isoflavone Metabolites in Lipopolysaccharide-stimulated Microglial Cells.

Authors:
  • Park Jin-Sun
  • Woo Moon-Sook
  • Kim Dong-Hyun
  • Hyun Jin-Won
  • Kim Won-Ki
  • Lee Jae-Chul
  • Kim Hee-Sun

From: Department of Neuroscience, College of Medicine, Ewha Womans University, Mok-6-dong 911-1, Yangchun-Ku, Seoul 158-710, South Korea.

The Journal of pharmacology and experimental therapeutics

  • Publish Date: Mar 2007
  • ISSN: 0022-3565
  • Volume: 320
  • Issue: 3
  • Pages: 1237-45
  • Medium: Print
  • Language: English
  • Citation (JAMA): Park Jin-Sun, Woo Moon-Sook, Kim Dong-Hyun, et al. Anti-inflammatory Mechanisms of Isoflavone Metabolites in Lipopolysaccharide-stimulated Microglial Cells.. J. Pharmacol. Exp. Ther. Mar 2007;320:1237-45

Abstract

The microglial activation plays an important role in neurodegenerative diseases by producing several proinflammatory cytokines and nitric oxide (NO). We found that three types of isoflavones and their metabolites that are transformed by the human intestinal microflora suppress lipopolysaccharide (LPS)-induced release of NO and tumor necrosis factor (TNF)-alpha in primary cultured microglia and BV2 microglial cell lines. The inhibitory effect of the isoflavone metabolites (aglycon form) was more potent than that of isoflavones (glycoside form). The RNase protection assay showed that the isoflavone metabolites regulated inducible nitric oxide synthase (iNOS) and the cytokines at either the transcriptional or post-transcriptional level. A further molecular mechanism study was performed for irisolidone, a metabolite of kakkalide, which had the most potent anti-inflammatory effect among the six isoflavones tested. Irisolidone significantly inhibited the DNA binding and transcriptional activity of nuclear factor (NF)-kappaB and activator protein-1. Moreover, it repressed the LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation without affecting the activity of c-Jun N-terminal kinase or p38 mitogen-activated protein kinase. The level of NF-kappaB inhibition by irisolidone correlated with the level of iNOS, TNF-alpha, and interleukin (IL)-1beta suppression in LPS-stimulated microglia, whereas the level of ERK inhibition correlated with the level of TNF-alpha and IL-1beta repression. Overall, the repression of proinflammatory cytokines and iNOS gene expression in activated microglia by isoflavones such as irisolidone might have therapeutic potential for various neurodegenerative diseases including ischemic cerebral disease.

Mesh Headings (Keywords): Animals, Anti-Inflammatory Agents, Non-Steroidal, Cell Line, Cell Survival, Cytokines, DNA-Binding Proteins, Gene Expression, Isoflavones, Lipopolysaccharides, Mice, Microglia, Molecular Structure, Nitric Oxide Synthase Type II, Pueraria, Ribonucleases


Check for Full Text / PubMed Unique Identifier (PMID): 17194798


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.